Posted by Michael Wonder on 09 Jan 2024
Zevra Therapeutics receives FDA acceptance of resubmission of NDA for arimoclomol as a treatment for Niemann-Pick disease type C
8 January 2024 - Arimoclomol NDA has been assigned a PDUFA action date of 21 June 2024.
Zevra Therapeutics today announced that the US FDA has acknowledged receipt of the resubmission of the new drug application for arimoclomol as an orally delivered, first in class treatment for Niemann-Pick disease type C.
